Letter to the Editor
Copyright ©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 417-422
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.417
Table 1 Baseline characteristics of patients treated with second-line Nal-iri at the Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
Baseline characteristics
Patients, %
Sex
Male71
Female 29
Age, yr
< 65 36
≥ 6564
Location of primary tumour
Head-uncinate process57
Body21.5
Tail 21.5
Previous surgery
Yes28.5
No71.5
Number of metastatic sites
Single site36
Multiple sites64
Location of metastatic sites
Lymph nodes78.5
Liver57
Peritoneum42.8
Lung35.7
First-line chemotherapy regimen
Gemcitabine-nab-paclitaxel92.8
Other7.2